Indication: Major Adverse Cardiovascular Events (MACE)
SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
Sub-indication: Major Adverse Cardiovascular Events (MACE)
Study Type: Drug Study
Principal Investigator: Joseph Lash, M.D.Norton Heart & Vascular Institute
Sponsor: Sponsor: Novo Nordisk, Inc.
Learn more at ClinicalTrials.gov
Email for more information: NCRG@nortonhealthcare.org